RESUMEN
Irradiated malaria sporozoites can induce CD8+ T cells that are required for protection against infection. However, the parasite antigens targeted by this immune response are unknown. We have discovered a 16-amino acid epitope from the Plasmodium yoelii circumsporozoite (CS) protein that is recognized by cytotoxic T cells from immune mice. Lymphocytes stimulated with this peptide can kill P. yoelii liver stage parasites in vitro in an MHC-restricted, antigen-specific manner. Thus, epitopes from the CS protein are presented on the surface of infected hepatocytes and can be targets for T cells, even though intact CS protein has not been detected on the surface of the infected hepatocyte. A vaccine that induced CTL to parasite antigens might protect humans against malaria by eliminating liver stage parasites.
Asunto(s)
Hígado/parasitología , Fragmentos de Péptidos/inmunología , Plasmodium yoelii/inmunología , Proteínas Protozoarias/inmunología , Linfocitos T Citotóxicos/inmunología , Animales , Epítopos/análisis , Femenino , Inmunización , Hígado/inmunología , Malaria/inmunología , Ratones , Ratones Endogámicos BALB C , Vacunas/inmunologíaRESUMEN
Circumsporozoite (CS) proteins, which densely coat malaria (Plasmodia) sporozoites, contain an amino acid sequence that is homologous to segments in other proteins which bind specifically to sulfated glycoconjugates. The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates. To test this hypothesis, recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses. CS protein bound avidly to heparin-, fucoidan-, and dextran sulfate-Sepharose, but bound comparatively poorly to chondroitin sulfate A- or C-Sepharose. CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild-type line, consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells. This possibility is consistent with the observation that CS protein binding to hepatocytes, cells invaded by sporozoites during the primary stage of malaria infection, was inhibited by fucoidan, pentosan polysulfate, and heparin. The effects of sulfated glycoconjugates on sporozoite infectivity were also determined. P. berghei sporozoites bound specifically to sulfatide (galactosyl[3-sulfate]beta 1-1ceramide), but not to comparable levels of cholesterol-3-sulfate, or several examples of neutral glycosphingolipids, gangliosides, or phospholipids. Sporozoite invasion into hepatocytes was inhibited by fucoidan, heparin, and dextran sulfate, paralleling the observed binding of CS protein to the corresponding Sepharose derivatives. These sulfated glycoconjugates blocked invasion by inhibiting an event occurring within 3 h of combining sporozoites and hepatocytes. Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan. Taken together, these data indicate that CS proteins bind selectively to certain sulfated glycoconjugates, that sporozoite infectivity can be inhibited by such compounds, and that invasion of host hepatocytes by sporozoites may involve interactions with these types of compounds.
Asunto(s)
Antígenos de Protozoos/metabolismo , Glicoconjugados/metabolismo , Plasmodium/metabolismo , Proteínas Protozoarias , Secuencia de Aminoácidos , Animales , Femenino , Heparitina Sulfato/genética , Heparitina Sulfato/metabolismo , Hígado/microbiología , Malaria/parasitología , Malaria/prevención & control , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia MolecularRESUMEN
An in vitro model was developed to study the hepatic phase of Plasmodium falciparum, the only malaria parasite lethal to man. Primary cultures of human hepatocytes were inoculated with sporozoites of Brazilian and African strains of P. falciparum. On days 1 through 7 after inoculation examination of fluorescence-labeled and Giemsa-stained preparations demonstrated the presence of many intracellular parasites. In three separate sets of experiments all cultures were found to be infected with as many as 650 liver schizonts measuring up to 40 micrometers. After the addition of red blood cells, intraerythrocytic forms of P. falciparum were detected on days 12 and 13 by an immunofluorescence assay, indicating that the hepatic cycle had been completed in vitro.
Asunto(s)
Hígado/parasitología , Plasmodium falciparum/crecimiento & desarrollo , Animales , Colorantes Azulados , Células Cultivadas , Medios de Cultivo , Eritrocitos/parasitología , Técnica del Anticuerpo Fluorescente , Plasmodium falciparum/citología , Factores de TiempoRESUMEN
Antibodies were raised in mice immunized with several recombinant and synthetic peptides of the circumsporozoite protein of Plasmodium falciparum. The antibodies were evaluated for protective activity in a human hepatocyte culture system. They exerted their protective effect against the parasite at three points: sporozoite attachment to the hepatocyte surface, entry, and subsequent intracellular development. Inhibition of attachment and entry were found to be related to the antibody titer against the authentic circumsporozoite protein on the sporozoite surface, especially when peptides were administered with alum or complete Freund's adjuvant. Even when invasion was not totally inhibited, the presence of abnormal trophozoites and a frequent inhibition of schizont development in long-term cultures suggested continued activity of antibodies at the intracellular level after sporozoite penetration had been completed.
Asunto(s)
Anticuerpos/inmunología , Antígenos de Protozoos/inmunología , Plasmodium falciparum/inmunología , Animales , Técnica del Anticuerpo Fluorescente , Humanos , Técnicas In Vitro , Hígado/citología , Hígado/parasitología , Ratones , Péptidos/inmunología , Proteínas Recombinantes/inmunologíaRESUMEN
To address the question of how many distinct parasites are injected when a mosquito bites, we have characterized isolates resulting most probably from a single sporozoite inoculum. We describe the direct and immediate cloning on hepatocyte feeder layers of a Thai and an African Plasmodium falciparum primary isolate and the characterization of 67 independent clones by four techniques totaling nine different markers. This led to three main conclusions: (a) both the phenotypic and genotypic markers revealed an unexpectedly large degree of diversity within the clones from a single isolate; (b) the clones are nonetheless genetically related; and (c) a single mosquito inoculum would most likely be sufficient to generate considerable isolate complexity in the absence of repeated exposure. This diversity, which has been greatly underestimated in previous studies, does not bode well for the development of successful malaria control means.
Asunto(s)
Variación Genética , Malaria Falciparum/parasitología , Plasmodium falciparum/genética , Polimorfismo de Longitud del Fragmento de Restricción , África , Animales , Antimaláricos/farmacología , Biomarcadores , Cloroquina/farmacología , Células Clonales , Culicidae/parasitología , Resistencia a Medicamentos , Humanos , Mordeduras y Picaduras de Insectos , Mefloquina/farmacología , Parasitología/métodos , Fenotipo , Plasmodium falciparum/aislamiento & purificación , Reacción en Cadena de la Polimerasa , Quinina/farmacología , TailandiaRESUMEN
The expression of the pfemp3 gene and the corresponding PfEMP3 knob-associated protein in the pre-erythrocytic stages of Plasmodium falciparum was demonstrated by RT-PCR, Western blots, IFAT and IEM. The antigen was found on the surface of the sporozoite and in the cytoplasm of mature hepatic stage parasites. Immunological cross-reactivity was observed with sporozoites from the rodent malaria parasites Plasmodium yoelii yoelii and Plasmodium berghei and was exploited to assess a potential role of this protein at the pre-erythrocytic stages. Specific antibodies from immune individuals were found to inhibit P. yoelii yoelii and P. berghei sporozoite invasion of primary hepatocyte cultures. PfEMP3 should now be added to the small list of proteins expressed at the pre-erythrocytic stages of P. falciparum, and its vaccine potential now deserves to be investigated.
Asunto(s)
Antígenos de Protozoos/inmunología , Antígenos de Protozoos/metabolismo , Proteínas de la Membrana/inmunología , Proteínas de la Membrana/metabolismo , Plasmodium falciparum/crecimiento & desarrollo , Plasmodium falciparum/inmunología , Animales , Anticuerpos Antiprotozoarios/inmunología , Antígenos de Protozoos/genética , Antígenos de Protozoos/ultraestructura , Western Blotting , Clonación Molecular , Secuencia Conservada , Reacciones Cruzadas/inmunología , Epítopos/inmunología , Eritrocitos/parasitología , Técnica del Anticuerpo Fluorescente Indirecta , Regulación del Desarrollo de la Expresión Génica , Hepatocitos/parasitología , Humanos , Sueros Inmunes/inmunología , Malaria/inmunología , Malaria/parasitología , Proteínas de la Membrana/genética , Proteínas de la Membrana/ultraestructura , Microscopía Inmunoelectrónica , Plasmodium/inmunología , Plasmodium falciparum/genética , Plasmodium falciparum/metabolismo , Proteínas Protozoarias , ARN Protozoario/genética , ARN Protozoario/metabolismo , Proteínas RecombinantesRESUMEN
The observation that protective immunity induced by immunization with radiation attenuated Plasmodium berghei and Plasmodium yoelii sporozoites is dependent on CD8+ T lymphocytes in some strains of mice led us to speculate that immunization with sporozoites induces cytotoxic T lymphocytes (CTL) that recognize malaria antigens on the surface of malaria-infected hepatocytes. In this report we summarize a series of experiments that confirm this hypothesis. We first showed that when immune mice are challenged with live sporozoites they develop malaria-specific, CD8+ T cell-dependent infiltrates in their livers. Next we demonstrated that spleen cells from immune mice eliminate malaria infected hepatocytes from in vitro culture in an antigen specific and genetically restricted manner, indicating that these immune cells recognize malaria antigens on the surface of infected hepatocytes. Finally we defined a CTL epitope of the P. yoelii CS protein, and demonstrated that CTL against this 16-amino-acid peptide (PYCTL1) eliminate infected hepatocytes from culture in an antigenic specific, and MHC restricted manner, indicating that this 16-amino-acid peptide from the CS protein is present on the surface of the infected hepatocytes. We are currently working on constructing vaccines that induce protective CTL against PYCTL1, and identifying additional pre-erythrocytic stage targets of CTL mediated protective immunity.
Asunto(s)
Antígenos de Protozoos/inmunología , Antígenos de Superficie/inmunología , Hígado/parasitología , Plasmodium berghei/inmunología , Vacunas Antiprotozoos/inmunología , Linfocitos T Citotóxicos/inmunología , Animales , Técnicas In Vitro , Hígado/citología , Hígado/inmunología , Ratones , Ratones Endogámicos BALB C , Plasmodium berghei/efectos de la radiación , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/efectos de la radiación , Vacunas Atenuadas/inmunologíaRESUMEN
Nitric oxide (NO) produced by cytokine-treated macrophages and hepatocytes plays a vital role in protective host responses to infectious pathogens. NO inhibits iron-sulfur-dependent enzymes involved in cellular respiration, energy production, and reproduction. Synthesis of L-arginine-derived nitrite (NO2-), the oxidative end product of NO, directly correlates with intracellular killing of Leishmania major, an obligate intracellular protozoan parasite of macrophages: the level of NO2- production is a quantitative index for macrophage activation. The competitive inhibitor of NO synthesis, monomethylarginine (NGMMLA), inhibits both parasite killing and NO2- production. For Leishmania, the parasite itself participates in the regulation of this toxic effector mechanism. This participation is mediated by parasite induction of tumor necrosis factor alpha (TNF alpha), an autocrine factor of macrophages: NO synthesis by interferon-gamma (IFN-gamma)-treated cells can be blocked by monoclonal antibodies to TNF alpha. NO production by IFN gamma-treated hepatocytes is of special interest in malaria infections: sporozoite-infected hepatocytes kill the intracellular malaria parasite after treatment with IFN gamma; this killing is inhibited by NGMMLA.
Asunto(s)
Interferón gamma/fisiología , Hígado/inmunología , Macrófagos/inmunología , Óxido Nítrico/metabolismo , Enfermedades Parasitarias/inmunología , Animales , Arginina/metabolismo , Inmunidad Innata/fisiología , Técnicas In Vitro , Leishmania tropica/inmunología , Hígado/parasitología , Macrófagos/parasitología , Ratones , Plasmodium berghei/inmunologíaRESUMEN
The activity of desferrioxamine (Desferal) and desferrithiocin (a newly developed oral iron chelator) was evaluated against the liver stage of Plasmodium yoelii and P. falciparum in the rodent and the human hepatocyte in vitro culture system. The two iron chelators were found to inhibit the liver schizogony of both the rodent and the human Plasmodium species at concentrations achievable in vivo. P. falciparum proved to be more sensitive (ic 95% below 20 micromol/l than P. yoelii (ic 95% 50-100 micromol/l). As assessed by electron microscopy, drug administration was associated with focal clarification of the cytoplasm thought to be reversible. As desferrioxamine and desferrithiocin are known to be equally active on the blood stage of rodent and human plasmodia, iron chelators are deserving of further investigation as potential alternative candidates to existing drugs for radical cure of malaria.
Asunto(s)
Deferoxamina/farmacología , Dihidropiridinas/farmacología , Quelantes del Hierro/farmacología , Plasmodium falciparum/efectos de los fármacos , Plasmodium yoelii/efectos de los fármacos , Tiazoles/farmacología , Animales , Células Cultivadas , Deferoxamina/uso terapéutico , Deferoxamina/toxicidad , Dihidropiridinas/uso terapéutico , Dihidropiridinas/toxicidad , Humanos , Quelantes del Hierro/uso terapéutico , Quelantes del Hierro/toxicidad , Hígado/efectos de los fármacos , Hígado/parasitología , Hígado/ultraestructura , Malaria/tratamiento farmacológico , Microscopía Electrónica , Plasmodium falciparum/crecimiento & desarrollo , Plasmodium yoelii/crecimiento & desarrollo , Ratas , Tiazoles/uso terapéutico , Tiazoles/toxicidadRESUMEN
Circumsporozoite (CS) proteins, the major surface proteins of the sporozoites of the various malaria (Plasmodium) species, share a region of highly conserved sequence homology in common with sporozoite surface protein 2 (SSP2) and a group of proteins observed to specifically bind sulfated glycoconjugates. Recombinant P. yoelii CS protein was found to bind selectively to heparin-, fucoidan-, and dextran sulfate-Sepharose, but poorly to chondroitin sulfate A- or C-Sepharose. It also bound with lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild-type. Likewise, P. berghei sporozoite invasion into hepatocytes was selectively inhibited by fucoidan, heparin, and dextran sulfate, and sporozoites bound specifically to sulfatide [galactosyl (3-SO4) beta 1-1 ceramide] coated surfaces. Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan. Taken together, these data indicate that CS proteins bind selectively to certain sulfated glyconjugates and invasion of host hepatocytes by sporozoites, and sporozoite infectivity can be inhibited by such compounds.
Asunto(s)
Glicoconjugados/metabolismo , Plasmodium/metabolismo , Proteínas Protozoarias/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Sulfato de Dextran/metabolismo , Sulfato de Dextran/farmacología , Sulfato de Dextran/uso terapéutico , Glucolípidos/metabolismo , Heparina/metabolismo , Heparina/farmacología , Heparina/uso terapéutico , Malaria/prevención & control , Ratones , Datos de Secuencia Molecular , Plasmodium/efectos de los fármacos , Plasmodium/genética , Polisacáridos/metabolismo , Polisacáridos/farmacología , Polisacáridos/uso terapéutico , Unión Proteica , Proteínas Recombinantes/metabolismo , Homología de Secuencia de AminoácidoRESUMEN
Primary cultures of BALB/cJ hepatocytes treated with 10(3) U/ml rIFN-gamma consistently inhibited intracellular Plasmodium berghei liver schizont development by 50 to 70%. Monomethyl-L-arginine (NGMMLA), the competitive inhibitor of L-arginine as substrate for production of nitric oxides by hepatocytes, reversed the activity of IFN-gamma on these malaria-infected cells. Reversal of IFN-gamma activity by NGMMLA was dose dependent and was maximal at 0.5 mM NGMMLA. Depletion of L-arginine by addition of arginase to the culture medium blocked the capacity of IFN-gamma to inhibit parasite development in hepatocytes; addition of excess L-arginine to cultures treated with IFN-gamma in the presence of NGMMLA competitively restored IFN-gamma capacity to activate hepatocyte anti-parasite activity. TNF-alpha was neither required for IFN-gamma activity, nor effective at any concentration tested as an inhibitor of schizont development by itself in primary hepatocytes. These data strongly suggest that the action of IFN-gamma on P. berghei-infected hepatocytes is to induce the production of L-arginine-derived nitrogen oxides that are toxic for the intracellular parasite.
Asunto(s)
Arginina/fisiología , Interferón gamma/farmacología , Hígado/parasitología , Plasmodium berghei/efectos de los fármacos , Animales , Arginina/análogos & derivados , Arginina/farmacología , Células Cultivadas , Ratones , Ratones Endogámicos BALB C , Óxidos de Nitrógeno/metabolismo , Plasmodium berghei/crecimiento & desarrollo , Factor de Necrosis Tumoral alfa/fisiología , omega-N-MetilargininaRESUMEN
When mice are immunized with radiation-attenuated sporozoites they are solidly protected against sporozoite challenge by an immune response that has been shown to require CD8+ lymphocytes in several strains of mice. The target of this CD8+ T-cell-dependent immunity has not been established. Immune BALB/c mice were shown to develop malaria-specific, CD8+ T-cell-dependent inflammatory infiltrates in their livers after challenge with Plasmodium berghei sporozoites. Spleen cells from immune BALB/c and C57BL/6 mice eliminated hepatocytes infected with the liver stage of P. berghei in vitro. The activity against infected hepatocytes is not inhibited by antibodies to interferon-gamma and is not present in culture supernatants. It is genetically restricted, an indication that malaria antigens on the hepatocyte surface are recognized by immune T-effector cells. Further subunit pre-erythrocytic stage malaria vaccine development will require identification of the antigens recognized by these T cells and a method of immunization that induces such immunity.
Asunto(s)
Inmunoterapia Adoptiva , Hígado/parasitología , Plasmodium berghei/inmunología , Linfocitos T Reguladores/inmunología , Animales , Anticuerpos , Células Cultivadas , Interferón gamma/inmunología , Hígado/citología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Plasmodium berghei/efectos de la radiación , Proteínas RecombinantesRESUMEN
Expression of inducible nitric oxide (NO) synthase has been shown to inhibit the development of several pathogens, including fungi, bacteria, parasites, and viruses. However, there is still controversy as to whether this effector mechanism can inhibit the development of human pathogens. We now report that gamma interferon (IFN-gamma) induces the elimination of Plasmodium falciparum-infected primary human hepatocytes from cultures and that the antimalarial activity is dependent on NO. Infection with the parasite alone in the absence of added IFN-gamma caused a 10-fold increase in NO formation. Both spontaneous inhibition and IFN-gamma-induced inhibition of Plasmodium yoelii-infected murine hepatocytes were increased with the addition of the NO synthase cofactor tetrahydrobiopterin, or sepiapterin, which is converted to tetrahydrobiopterin. These results indicate that under in vitro conditions the parasite itself provides a signal that triggers induction of the NO pathway in human and murine hepatocytes and that NO formation in infected hepatocytes is limited by tetrahydrobiopterin availability.
Asunto(s)
Biopterinas/análogos & derivados , Interferón gamma/farmacología , Hígado/parasitología , Óxido Nítrico/fisiología , Plasmodium/efectos de los fármacos , Animales , Biopterinas/farmacología , Células Cultivadas , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Plasmodium/crecimiento & desarrolloRESUMEN
Primary cultures of human hepatocytes, a culture-derived clone from the human hepatoma Hep G2 line, and cultured rat hepatocytes were inoculated in vitro with Plasmodium ovale sporozoites extracted from Anopheles stephensi, An. gambiae, and An. dirus mosquitoes. Penetration and differentiation of P. ovale sporozoites into trophozoite stage parasites occurred in all three cell types, but with a lower transformation rate in the Hep G2 cell line than in the primary cultured hepatocytes. Further maturation was obtained only in the human hepatocytes, in which the parasites were uninucleate until the third day after infection, before development to 60 micron in length by the eighth day. Additionally, this culture system was used to assess the ability of an anti-P. ovale sporozoite monoclonal antibody to inhibit penetration of sporozoites into hepatocytes and to detect sporozoite determinants in the maturing liver stage parasites.
Asunto(s)
Hígado/parasitología , Plasmodium/crecimiento & desarrollo , Animales , Anticuerpos Monoclonales , Anticuerpos Antiprotozoarios/inmunología , Células Cultivadas , Humanos , Hígado/citología , Malaria/parasitología , RatasRESUMEN
In Balb/c mice, the sterile protective immunity induced by immunization with radiation-attenuated Plasmodium yoelii sporozoites is eliminated by in vivo depletion of CD8+ T lymphocytes, suggesting that cytotoxic T lymphocytes (CTL) against malaria antigens expressed on infected hepatocytes are required for mediating this protective immunity. To produce a vaccine that would induce CTL against the P. yoelii circumsporozoite protein (CS), we constructed an attenuated pseudorabies virus (PRV) containing a gene encoding this protein. Balb/c mice that received three doses of 10(7) plaque-forming units (p.f.u.) of this vaccine intravenously at 3 week intervals developed high levels of antibodies to sporozoites (indirect fluorescent antibody titre = 4096) and CTL against a 16 amino acid epitope (SYVPSAEQILEFVKQI, amino acids 281-296) from the P. yoelii CS protein designated PYCTL1. The cytotoxic activity of the CTL was antigen-specific, MHC-restricted, and dependent on CD8+ T cells. Furthermore, these CTL eliminated P. yoelii-infected hepatocytes from in vitro culture, indicating that they recognize this peptide on the surface of infected hepatocytes. However, all nine mice that were challenged with 200 sporozoites developed a blood-stage malaria infection. We attribute this lack of protection to the great difficulty of inducing sterile immunity against this highly infectious parasite P. yoelii. We conclude that recombinant pseudorabies virus (PRV) worked successfully as a live vaccine vector to induce both antibodies and CTL, albeit non-protective in vivo, and the herpesviruses should be considered as subunit vaccines where T- and B-cell immunity is required.
Asunto(s)
Antígenos de Protozoos/genética , Malaria/inmunología , Plasmodium yoelii/genética , Plasmodium yoelii/inmunología , Proteínas Protozoarias , Secuencia de Aminoácidos , Animales , Anticuerpos Antiprotozoarios/biosíntesis , Antígenos de Protozoos/inmunología , Linfocitos B/inmunología , Femenino , Vectores Genéticos/inmunología , Herpesvirus Suido 1/genética , Inmunidad , Inmunización , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Péptidos/genética , Péptidos/inmunología , Linfocitos T Citotóxicos/inmunologíaRESUMEN
We have studied the effect of natural and recombinant human interferons (HuIFN-alpha, -beta, and -gamma), and interleukin 1 (IL-1) on development of sporozoites of Plasmodium falciparum in cultures of functional hepatocytes. HuIFN-gamma inhibits hepatic schizogony of P. falciparum at very low concentrations (0.1 to 10 international units/ml), the target being the hepatocyte. Application after sporozoite inoculation is effective, suggesting an intracellular mechanism. There is also an 84% inhibition after application from 4 to 6 days following inoculation so that by day 6, there was a disappearance of a significant number of schizonts previously present at day 4, indicating more than a parasitostatic effect, and probably a postassembly action. HuIFN-alpha and -beta were effective, but only at 1000-fold higher concentrations than HuIFN-gamma. IL-1 (5 U/ml) also inhibited hepatic development of P. falciparum sporozoites; however, IL-1 treatment was effective only when applied before sporozoite inoculation.
Asunto(s)
Interferones/farmacología , Interleucina-1/farmacología , Hígado/parasitología , Plasmodium falciparum/efectos de los fármacos , Animales , Células Cultivadas , Humanos , Plasmodium/efectos de los fármacos , Plasmodium/crecimiento & desarrollo , Plasmodium falciparum/crecimiento & desarrollo , Ratas , Proteínas Recombinantes/farmacología , Factores de TiempoRESUMEN
We have evaluated the in vitro biological activities of antibodies directed against sporozoites and compared them with their capacity to protect against challenge with both human and rodent malaria. The anti-Plasmodium falciparum antibodies evaluated with the test included monoclonal antibodies (MAbs) NFS1 and NFS2 as well as polyclonal antibodies contained in human hyperimmune sera directed against sporozoites of P. falciparum. The inhibitory effect of these antibodies was dependent on their concentration. However, total inhibition was not observed except occasionally with highly concentrated MAbs (10-100 micrograms/ml). Strong but also incomplete inhibition was observed with sera from humans living in hyperendemic areas. In the P. yoelii rodent system, we tested sera from mice immunized with subunit vaccines. None of these mice were protected in vivo against challenge with 40-200 sporozoites. In vitro only a sub-total inhibition was achieved (maximum 91% at 1:10 serum dilution). In contrast, we tested sera from mice that received NYS1, an IgG3 MAb, in passive transfer and were protected against challenge with 5000 sporozoites. At 1:10 dilution, 100% inhibition was achieved in vitro while IFA titres from these mice were similar to those of vaccinated mice. These data show a close correlation between in vivo and in vitro findings and thus suggest that the inhibition of liver-stage development assay (ILSDA) appears appropriate to evaluate the potential of antibodies.
Asunto(s)
Anticuerpos Antiprotozoarios/aislamiento & purificación , Malaria/prevención & control , Plasmodium falciparum/inmunología , Plasmodium yoelii/inmunología , Adulto , Anciano , Animales , Anticuerpos Monoclonales/inmunología , Técnica del Anticuerpo Fluorescente , Humanos , Sueros Inmunes/inmunología , Inmunización Pasiva , Técnicas In Vitro , Hígado/citología , Ratones , Ratones Endogámicos BALB C , Persona de Mediana EdadRESUMEN
One of the primary strategies for malaria vaccine development has been to design subunit vaccines that induce protective levels of antibodies against the circumsporozoite (CS) protein of malaria sporozoites. In the Plasmodium yoelii mouse model system such vaccines have been uniformly unsuccessful in protecting against sporozoite-induced malaria. To demonstrate that antibodies to P. yoelii CS protein could provide protection we established a passive transfer model. Passive transfer of Navy yoelii sporozoite 1 (NYS1), an IgG3 mAb against the P. yoelii CS protein, protected 100% of mice against challenge with 5000 P. yoelii sporozoites. Binding of NYS1 to sporozoites was inhibited by incubation with (QGPGAP)2, a synthetic peptide derived from the repeat region of the P. yoelii CS protein, indicating that the epitope on sporozoites recognized by this mAb was included within this peptide. The levels of antibodies to (QGPGAP)2 by ELISA, and to sporozoites by indirect fluorescent antibody test and CS precipitation reaction were similar in sera from mice that received NYS1 in passive transfer and were protected against challenge with 5000 sporozoites, and from mice that had been immunized with subunit vaccines containing (QGPGAP)2 but were not protected against challenge with 40-200 sporozoites. To determine if antibody avidity, not absolute concentration could explain the striking differences in protection, we established a thiocyanate elution assay. The results suggest that NYS1, the protective mAb, has a lower avidity for (QGPGAP)2 and for sporozoites than do the vaccine-induced antibodies. Although the results of the conventional antibody assays did not correlate with protection, sera from the protected animals inhibited sporozoite development in mouse hepatocyte cultures significantly more than did the sera from the unprotected, subunit vaccine-immunized animals, correlating with protection. The data clearly demonstrate that antibodies to the CS protein can protect against intense sporozoite infection. Improved understanding of the differences between protective mAb and nonprotective polyclonal antibodies will be important in the further development of malaria vaccines.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Plasmodium yoelii/inmunología , Animales , Anticuerpos Antiprotozoarios/análisis , Femenino , Inmunización Pasiva , Inmunoglobulina G/análisis , Malaria/prevención & control , Ratones , Ratones Endogámicos BALB C , Vacunas Antiprotozoos/inmunologíaRESUMEN
Immunization of mice with Plasmodium yoelii sporozoite surface protein 2 (PySSP2) and circumsporozoite protein protects completely against P. yoelii. The amino acid sequence of PySSP2 suggested that the thrombospondin-related anonymous protein (TRAP) [Robson, K. J. H., Hall, J. R. S., Jennings, M. W., Harris, T. J. R., Marsh, K., Newbold, C. I., Tate, V. E. & Weatherall, D. J. (1988) Nature (London) 335, 79-82] is the Plasmodium falciparum homolog of PySSP2. We report data confirming that TRAP is P. falciparum SSP2 (PfSSP2). Murine antibodies against recombinant PfSSP2 identify a 90-kDa protein in extracts of P. falciparum sporozoites, recognize sporozoites and infected hepatocytes by immunofluorescence, localize PfSSP2 to the sporozoite micronemes by immunoelectron microscopy and to the surface membrane by live immunofluorescence, and inhibit sporozoite invasion and development in hepatocytes in vitro. Human volunteers immunized with irradiated sporozoites and protected against malaria develop antibody and proliferative T-cell responses to PfSSP2, suggesting that, like PySSP2, PfSSP2 is a target of protective immunity, and supporting inclusion of PfSSP2 in a multicomponent malaria vaccine.
Asunto(s)
Antígenos de Protozoos/genética , Plasmodium falciparum/genética , Proteínas Protozoarias/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Western Blotting , Clonación Molecular , Activación de Linfocitos , Microscopía Inmunoelectrónica , Datos de Secuencia Molecular , Oligodesoxirribonucleótidos , Plasmodium falciparum/ultraestructura , Reacción en Cadena de la Polimerasa/métodos , Proteínas Protozoarias/ultraestructura , Secuencias Repetitivas de Ácidos Nucleicos , Linfocitos T/inmunologíaRESUMEN
We have previously identified a Plasmodium falciparum liver stage-specific Ag (LSA-1) found to encode tandem 17 amino acid repeats harboring B cell determinants. Here we extend this study in terms of sequence analysis, protein localization, and immunologic properties. Analysis of the N- and C-terminal regions of LSA-1 from the T9/96 clone reveals high sequence conservation with LSA-1 from NF54. This 200-kDa protein is detected throughout liver schizogony and accumulates in the parasitophorous vacuole space. In our investigation of T and B cell responses to LSA-1, we have focused on both the area of the C-terminal, nonrepetitive "hinge" region and the conserved repetitive region and derived synthetic peptides. These were found to contain major B and T cell determinants. High prevalences and elevated Ab levels to LSA-1, directed primarily, although not exclusively, to the repetitive region, were detected in sera of individuals from one moderately high and two low transmission malaria-endemic areas (prevalences of 97%, 75, and 77%, respectively). In one of these low transmission areas, secretion of the cytokine IFN-gamma, known to inhibit malaria liver stages, and T cell proliferation were detected in PBMC of 22 to 48% and 6 to 20%, respectively, of individuals in response to separate LSA-1 peptides. These results complement the recent finding of conserved CTL epitopes in LSA-1 and support the assertion that immune responses to LS Ag are involved in protection against malaria pre-erythrocytic stages.